Rosamond Deegan (OMass)

Uni­ver­si­ty of Ox­ford spin­off nets a nine-fig­ure Se­ries B, but it won't bee­line to­ward the clin­ic

Four years af­ter com­plet­ing a Se­ries A, an Ox­ford spin­out has re­turned to the ven­ture well and gar­nered in­ter­est for how its tech­nol­o­gy is be­ing ap­plied to drug dis­cov­ery.

OMass Ther­a­peu­tics has raised $100 mil­lion in a Se­ries B round with par­tic­i­pants that in­clude GV, North­pond Ven­tures and Sanofi Ven­tures. Syn­cona, Ox­ford Sci­ence En­ter­pris­es and the Uni­ver­si­ty of Ox­ford, who were a part of the Se­ries A round, al­so par­tic­i­pat­ed this time around.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.